Dewpoint Therapeutics

Boston, MA · Founded 2018 · Privately Held (backing)

Developer of an AI-powered healthcare technology platform designed to identify novel drugs across a wide spectrum of diseases. Dewpoint Therapeutics is based in Boston, MA and was founded in 2018. Its last reported valuation was $500 million in Feb 2022. It has raised $345 million across 3 recorded rounds; the latest was a $59.1 million later-stage round in Sep 2025.

Last reported valuation
$500.0M
Oct 2026
Priced at
—
Total raised
$345.3M
Last round
Later Stage VC
Sep 2025

Who backs Dewpoint Therapeutics?

18 investors
InvestorType
General CatalystVenture capital
SoftBank Investment AdvisersGrowth equity
Alexandria Venture InvestmentsOther
Mirae Asset CapitalVenture capital
ARCH Venture PartnersVenture capital
Innovation EndeavorsVenture capital
Polaris PartnersVenture capital
Samsara BioCapitalVenture capital
Maverick VenturesHedge fund
EcoR1 CapitalHedge fund
+ 8 more investors · a free account shows the complete list
The directory is free. Investor activity — the working column — is Pro.Unlock prospecting columns

Membership and data by Private Market View

Dewpoint Therapeutics investors

18 investors are on record for Dewpoint Therapeutics, including General Catalyst, SoftBank Investment Advisers, Alexandria Venture Investments and Mirae Asset Capital. By type, the record holds 7 venture capital firms, 2 hedge funds and 1 growth equity firm. The later-stage round in Sep 2025 drew 21 investors.

Free account
More of Dewpoint Therapeutics with a free account
  • ·The complete investor list: 18 names
  • ·Watch Dewpoint Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

For fundraisers
Work this list, don’t just read it

These 18 firms already write checks for companies like Dewpoint Therapeutics. Build the wider list: every firm that has backed a company like this one, ranked by how often and how recently.

Find investors like these →

Membership and data by Private Market View